MENU

Men To File Lawsuit Over Antipsychotic Drug Risperdal That Caused Them To Grow Breasts

Close

Men who have used Risperdal (risperidone) are preparing to sue Johnson & Johnson for the serious side effects of taking the medication.

Drug For Mental And Mood Disorders

The drug, which is used to treat certain mental and mood disorders such as anxiety, bipolar disorder, and schizophrenia, is causing teen boys and men to grow breasts, a condition known as gynecomastia.

Eddie Bible was 13 years old when he suffered from the drug's side effect, which was not disclosed at the time he used the medication. He is among thousands of men preparing to file lawsuit against Risperdal maker Johnson & Johnson for not disclosing the possible side effects of the drug in a timely manner.

"They put me on this Risperdal. The doctors said, 'Well, Risperdal was helping some.' To me, it didn't really help, because a year and a half later, I had gynecomastia," Bible said adding that what he went through was humiliating. "I feel like an experiment."

Bible, who took the medication in the early 2000s, said that he would have never taken the drug if he was aware of its side effect. He said that the psychological impact of dealing with the side effects of the drugs such as isolating himself and dealing with how people reacted when they see a "boy with boobs" was worse than having bipolar disorder.

The antipsychotic drug has already been on the market for more than a decade in 2006 when the gynecomastia side effect was placed on its labels. For Bible and other teenage boys who took Risperdal earlier it was already too late.

Since 1994 when the drug was placed on the market, Risperdal has drawn attention and controversy. Johnson & Johnson and its subsidiary Janssen Pharmaceuticals, Inc. have been accused of hiding evidence that would have alerted regulatory authorities and clinicians of the link among Risperdal, increased level of the hormone prolactin known to promote milk production and gynecomastia.

Latest Risperdal Case Dismissed

On Tuesday, Philadelphia Court of Common Pleas Judge Sean Kennedy dismissed the latest trial over the drug, saying that the testimony of Mark Solomon, who has testified in almost all of Risperdal cases was inadequate.

"At the conclusion of my research and my staff's research, it is my opinion that under Texas law, Dr. Solomon's testimony is legally insufficient to prove causation in this case, and as such, I am granting defendant's motion for compulsory nonsuit," Kennedy said.

ⓒ 2018 TECHTIMES.com All rights reserved. Do not reproduce without permission.
Real Time Analytics